Eli Lilly wins FDA approval for less-frequent eczema drug dosing
Eli Lilly (NYSE:LLY) secured U.S. regulatory approval for a less-frequent dosing regimen of its eczema treatment Ebglyss, providing patients with a maintenance option that significantly reduces the annual injection burden.
The U.S. Food and Drug Administration cleared an every-eight-week maintenance schedule of the drug for adults and adolescents aged 12 and older weighing at least 40 kilograms who suffer from moderate-to-severe atopic dermatitis.
The updated approval allows patients to manage their chronic skin condition with as few as six single 250 mg subcutaneous injections per year, offering a substantial alternative to the previously standard once-monthly routine.
A notable feature of the updated protocol is that it delivers sustained disease management without requiring the simultaneous use of prescription topical treatments from the initiation of therapy.
Regulators based the decision on longitudinal exposure-response modeling alongside supportive clinical data from the Phase 3 ADjoin long-term extension trial, which evaluated the safety and efficacy of the extended dosing intervals over a 32-week period.
Ebglyss, known chemically as lebrikizumab-lbkz, is a targeted monoclonal antibody designed to neutralize interleukin-13, a primary cytokine driving the inflammatory loop responsible for skin irritation and eczema symptoms.
The drug originally entered the U.S. market in late 2024, and this latest regulatory milestone aims to improve patient convenience in a highly competitive global immunology landscape.
Under the updated guidelines, patients can transition to the eight-week maintenance schedule once adequate clinical response is achieved following the initial 16-week induction phase.
